{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:36:02Z","timestamp":1791974162323,"version":"4.4.0"},"reference-count":38,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T00:00:00Z","timestamp":1565827200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2019-0017_s_001_w2aab3b7b3b1b6b1aab1c16b1Aa\">\n                    <jats:title id=\"d1310192e6334_w2aab3b7b3b1b6b1aab1c16b1aAa\">Background<\/jats:title>\n                    <jats:p>Optimization of intraperitoneal drug delivery systems requires functional models. We proposed the Inverted Bovine Urinary Bladder Model (IBUB), but IBUB does not allow repeated measurements over time and there is a significant biological variability between organs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0017_s_002_w2aab3b7b3b1b6b1aab1c16b2Aa\">\n                    <jats:title id=\"d1310192e6343_w2aab3b7b3b1b6b1aab1c16b2aAa\">Methods<\/jats:title>\n                    <jats:p>\n                      A further development of IBUB is presented, based on the physical principle of communicating vessels. Fresh bovine bladders were inverted so that the peritoneum lines up the inner surface. The IBUB and a second vessel were then interconnected under the same CO\n                      <jats:sub>2<\/jats:sub>\n                      pressure and placed on two scales. The therapeutic solution (Doxorubicin 2.7\u2009mg and Cisplatin 13.5\u2009mg) was delivered via an aerosolizer. All experiments were in triplicate and blinded to the origin of samples, measurements in a GLP-certified laboratory.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0017_s_003_w2aab3b7b3b1b6b1aab1c16b3Aa\">\n                    <jats:title id=\"d1310192e6355_w2aab3b7b3b1b6b1aab1c16b3aAa\">Results<\/jats:title>\n                    <jats:p>The enhanced IBUB (eIBUB) model allows measurements of tissue drug concentration, depth of tissue penetration and spatial distribution. The homogeneous morphology of the peritoneum enables standardized, multiple tissue sampling. eIBUB minimizes biological variability between different bladders and eliminates the bias caused by the liquid collecting at the bottom of the model. Concentration of doxorubicin in the eIBUB (mean\u2009\u00b1\u2009STDV: 18.5\u2009\u00b1\u200922.6\u2009ng\/mg) were comparable to clinical peritoneal biopsies (19.2\u2009\u00b1\u200938.6\u2006ng\/mg), as was depth of drug penetration (eIBUB: mean (min-max) 433 (381\u2013486) \u00b5m, clinical\u2009~\u2009500\u2006\u00b5m).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0017_s_004_w2aab3b7b3b1b6b1aab1c16b4Aa\">\n                    <jats:title id=\"d1310192e6364_w2aab3b7b3b1b6b1aab1c16b4aAa\">Conclusions<\/jats:title>\n                    <jats:p>\n                      The eIBUB model is a simple and powerful\n                      <jats:italic>ex vivo<\/jats:italic>\n                      model for optimizing intraperitoneal drug delivery and represents an attractive alternative to animal models. Results obtained are similar to those obtained in the human patient.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2019-0017","type":"journal-article","created":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T06:08:06Z","timestamp":1565849286000},"source":"Crossref","is-referenced-by-count":15,"title":["A real-time\n                    <i>ex vivo<\/i>\n                    model (eIBUB) for optimizing intraperitoneal drug delivery as an alternative to living animal models"],"prefix":"10.1515","volume":"4","author":[{"given":"Iaroslav","family":"Sautkin","sequence":"first","affiliation":[{"name":"National Center for Pleura and Peritoneum , University of T\u00fcbingen , T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Solass","sequence":"additional","affiliation":[{"name":"Institute of Pathology , University of T\u00fcbingen , T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank-J\u00fcrgen","family":"Weinreich","sequence":"additional","affiliation":[{"name":"University of T\u00fcbingen , T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"K\u00f6nigsrainer","sequence":"additional","affiliation":[{"name":"Department of General and Transplant Surgery , University of T\u00fcbingen , T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schenk","sequence":"additional","affiliation":[{"name":"Experimental Surgical Oncology , Eberhard-Karls-Universitat Tubingen Medizinische Fakultat , T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolin","family":"Thiel","sequence":"additional","affiliation":[{"name":"Department of General and Transplant Surgery , University of T\u00fcbingen , T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Reymond","sequence":"additional","affiliation":[{"name":"National Center for Pleura and Peritoneum , University of T\u00fcbingen , T\u00fcbingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2019,8,15]]},"reference":[{"key":"2025120909273569346_j_pp-2019-0017_ref_001_w2aab3b7b3b1b6b1ab1b5b1Aa","doi-asserted-by":"crossref","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pi\u00f1eros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019;144:1941\u201353.10.1002\/ijc.3193730350310","DOI":"10.1002\/ijc.31937"},{"key":"2025120909273569346_j_pp-2019-0017_ref_002_w2aab3b7b3b1b6b1ab1b5b2Aa","doi-asserted-by":"crossref","unstructured":"Piso P, Arnold D. Multimodal treatment approaches for peritoneal carcinosis in colorectal cancer. Dtsch Arztebl Int 2011;108:802\u20138.22190994","DOI":"10.3238\/arztebl.2011.0802"},{"key":"2025120909273569346_j_pp-2019-0017_ref_003_w2aab3b7b3b1b6b1ab1b5b3Aa","doi-asserted-by":"crossref","unstructured":"Lambert LA. Looking up: recent advances in understanding and treating peritoneal carcinomatosis. CA Cancer J Clin 2015;65:284\u201398.25940594","DOI":"10.3322\/caac.21277"},{"key":"2025120909273569346_j_pp-2019-0017_ref_004_w2aab3b7b3b1b6b1ab1b5b4Aa","doi-asserted-by":"crossref","unstructured":"Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 2016:CD005340. DOI:10.1002\/14651858.CD005340.pub4.26755441","DOI":"10.1002\/14651858.CD005340.pub4"},{"key":"2025120909273569346_j_pp-2019-0017_ref_005_w2aab3b7b3b1b6b1ab1b5b5Aa","doi-asserted-by":"crossref","unstructured":"Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 1997;89:480\u20137.10.1093\/jnci\/89.7.4809086004","DOI":"10.1093\/jnci\/89.7.480"},{"key":"2025120909273569346_j_pp-2019-0017_ref_006_w2aab3b7b3b1b6b1ab1b5b6Aa","doi-asserted-by":"crossref","unstructured":"de Bree E, Michelakis D, Stamatiou D, Romanos J, Zoras O. Pharmacological principles of intraperitoneal and bidirectional chemotherapy. Pleura Peritoneum 2017;2:47\u201362.30911633","DOI":"10.1515\/pp-2017-0010"},{"key":"2025120909273569346_j_pp-2019-0017_ref_007_w2aab3b7b3b1b6b1ab1b5b7Aa","doi-asserted-by":"crossref","unstructured":"Kawanishi K. Diverse properties of the mesothelial cells in health and disease. Pleura Peritoneum 2016;1:79\u201389.30911611","DOI":"10.1515\/pp-2016-0009"},{"key":"2025120909273569346_j_pp-2019-0017_ref_008_w2aab3b7b3b1b6b1ab1b5b8Aa","doi-asserted-by":"crossref","unstructured":"Markman M. Chemotherapy: limited use of the intraperitoneal route for ovarian cancer-why? Nat Rev Clin Oncol 2015;12:628\u201330.10.1038\/nrclinonc.2015.17726462129","DOI":"10.1038\/nrclinonc.2015.177"},{"key":"2025120909273569346_j_pp-2019-0017_ref_009_w2aab3b7b3b1b6b1ab1b5b9Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH. Pharmacology of chemotherapy treatments for peritoneal metastases: optimizing and augmenting HIPEC. Pleura Peritoneum 2017;2:43\u20135.30911632","DOI":"10.1515\/pp-2017-0011"},{"key":"2025120909273569346_j_pp-2019-0017_ref_010_w2aab3b7b3b1b6b1ab1b5c10Aa","doi-asserted-by":"crossref","unstructured":"Lambert LA, Hendrix RJ. Palliative management of advanced peritoneal carcinomatosis. Surg Oncol Clin N Am 2018;27:585\u2013602.2993569110.1016\/j.soc.2018.02.008","DOI":"10.1016\/j.soc.2018.02.008"},{"key":"2025120909273569346_j_pp-2019-0017_ref_011_w2aab3b7b3b1b6b1ab1b5c11Aa","doi-asserted-by":"crossref","unstructured":"Evrard S, Mazi\u00e8re C, D\u00e9solneux G. HIPEC: standard of care or an experimental approach? Lancet Oncol 2012;13:e462\u20133.10.1016\/S1470-2045(12)70448-5","DOI":"10.1016\/S1470-2045(12)70448-5"},{"key":"2025120909273569346_j_pp-2019-0017_ref_012_w2aab3b7b3b1b6b1ab1b5c12Aa","doi-asserted-by":"crossref","unstructured":"K\u00f6nigsrainer A, Rau B. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): don\u2019t throw the baby out with the bathwater. Pleura Peritoneum 2018;3:20180131.30911670","DOI":"10.1515\/pp-2018-0131"},{"key":"2025120909273569346_j_pp-2019-0017_ref_013_w2aab3b7b3b1b6b1ab1b5c13Aa","doi-asserted-by":"crossref","unstructured":"Steuperaert M, Debbaut C, Segers P, Ceelen W. Modelling drug transport during intraperitoneal chemotherapy. Pleura Peritoneum 2017;2:73\u201383.30911635","DOI":"10.1515\/pp-2017-0004"},{"key":"2025120909273569346_j_pp-2019-0017_ref_014_w2aab3b7b3b1b6b1ab1b5c14Aa","doi-asserted-by":"crossref","unstructured":"Solass W, Kerb R, M\u00fcrdter T, Giger-Pabst U, Strumberg D, Tempfer C, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol 2014;21:553\u20139.10.1245\/s10434-013-3213-124006094","DOI":"10.1245\/s10434-013-3213-1"},{"key":"2025120909273569346_j_pp-2019-0017_ref_015_w2aab3b7b3b1b6b1ab1b5c15Aa","doi-asserted-by":"crossref","unstructured":"Alyami M, H\u00fcbner M, Grass F, Bakrin N, Villeneuve L, Laplace N, et al. Pressurized intraperitoneal aerosol chemotherapy: rationale, evidence and potential indications. Lancet Oncol 2019. (in press).","DOI":"10.1016\/S1470-2045(19)30318-3"},{"key":"2025120909273569346_j_pp-2019-0017_ref_016_w2aab3b7b3b1b6b1ab1b5c16Aa","doi-asserted-by":"crossref","unstructured":"Reymond M, Demtroeder C, Solass W, Winnekendonk G, Tempfer C. Electrostatic precipitation pressurized intraperitoneal aerosol chemotherapy (ePIPAC): first in-human application. Pleura Peritoneum 2016;1:109\u201316.30911614","DOI":"10.1515\/pp-2016-0005"},{"key":"2025120909273569346_j_pp-2019-0017_ref_017_w2aab3b7b3b1b6b1ab1b5c17Aa","doi-asserted-by":"crossref","unstructured":"Kakchekeeva T, Demtr\u00f6der C, Herath NI, Griffiths D, Torkington J, Sola\u00df W, et al. In vivo feasibility of electrostatic precipitation as an adjunct to pressurized intraperitoneal aerosol chemotherapy (ePIPAC). Ann Surg Oncol 2016;23:592\u20138.2684248710.1245\/s10434-016-5108-4","DOI":"10.1245\/s10434-016-5108-4"},{"key":"2025120909273569346_j_pp-2019-0017_ref_018_w2aab3b7b3b1b6b1ab1b5c18Aa","doi-asserted-by":"crossref","unstructured":"Khosrawipour V, Khosrawipour T, Diaz-Carballo D, F\u00f6rster E, Zieren J, Giger-Pabst U. Exploring the spatial drug distribution pattern of pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol 2016;23:1220\u20134.10.1245\/s10434-015-4954-926553440","DOI":"10.1245\/s10434-015-4954-9"},{"key":"2025120909273569346_j_pp-2019-0017_ref_019_w2aab3b7b3b1b6b1ab1b5c19Aa","doi-asserted-by":"crossref","unstructured":"Tempfer CB, Hilal Z, Dogan A, Petersen M, Rezniczek GA. Concentrations of cisplatin and doxorubicin in ascites and peritoneal tumor nodules before and after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal metastasis. Eur J Surg Oncol 2018;44:1112\u201317.2975361210.1016\/j.ejso.2018.04.020","DOI":"10.1016\/j.ejso.2018.04.020"},{"key":"2025120909273569346_j_pp-2019-0017_ref_020_w2aab3b7b3b1b6b1ab1b5c20Aa","doi-asserted-by":"crossref","unstructured":"Schnelle D, Weinreich FJ, Kibat J, Reymond MA. A new ex vivo model for optimizing distribution of therapeutic aerosols: the (inverted) bovine urinary bladder. Pleura Peritoneum 2017;2:37\u201341.30911631","DOI":"10.1515\/pp-2017-0006"},{"key":"2025120909273569346_j_pp-2019-0017_ref_021_w2aab3b7b3b1b6b1ab1b5c21Aa","doi-asserted-by":"crossref","unstructured":"Reymond MA, Hu B, Garcia A, Reck T, K\u00f6ckerling F, Hess J, et al. Feasibility of therapeutic pneumoperitoneum in a large animal model using a microvaporisator. Surg Endosc 2000;14:51\u20135.10.1007\/s004649900010","DOI":"10.1007\/s004649900010"},{"key":"2025120909273569346_j_pp-2019-0017_ref_022_w2aab3b7b3b1b6b1ab1b5c22Aa","doi-asserted-by":"crossref","unstructured":"Sola\u00df W, Hetzel A, Nadiradze G, Sagynaliev E, Reymond MA. Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc 2012;26:1849\u201355.2258086910.1007\/s00464-012-2148-0","DOI":"10.1007\/s00464-012-2148-0"},{"key":"2025120909273569346_j_pp-2019-0017_ref_023_w2aab3b7b3b1b6b1ab1b5c23Aa","doi-asserted-by":"crossref","unstructured":"Bellendorf A, Khosrawipour V, Khosrawipour T, Siebigteroth S, Cohnen J, Diaz-Carballo D, et al. Scintigraphic peritoneography reveals a non-uniform (99\u2006m)Tc-Pertechnetat aerosol distribution pattern for pressurized intra-peritoneal aerosol chemotherapy (PIPAC) in a swine model. Surg Endosc 2018;32:166\u201374.10.1007\/s00464-017-5652-4","DOI":"10.1007\/s00464-017-5652-4"},{"key":"2025120909273569346_j_pp-2019-0017_ref_024_w2aab3b7b3b1b6b1ab1b5c24Aa","doi-asserted-by":"crossref","unstructured":"Khosrawipour V, Khosrawipour T, Kern AJ, Osma A, Kabakci B, Diaz-Carballo D, et al. Distribution pattern and penetration depth of doxorubicin after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine model. J Cancer Res Clin Oncol 2016;142:2275\u201380.10.1007\/s00432-016-2234-0","DOI":"10.1007\/s00432-016-2234-0"},{"key":"2025120909273569346_j_pp-2019-0017_ref_025_w2aab3b7b3b1b6b1ab1b5c25Aa","doi-asserted-by":"crossref","unstructured":"Khosrawipour V, Khosrawipour T, Hedayat-Pour Y, Diaz-Carballo D, Bellendorf A, B\u00f6se-Ribeiro H, et al. Effect of whole-abdominal irradiation on penetration depth of doxorubicin in normal tissue after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a post-mortem swine model. Anticancer Res 2017;37:1677\u201380.10.21873\/anticanres.11498","DOI":"10.21873\/anticanres.11498"},{"key":"2025120909273569346_j_pp-2019-0017_ref_026_w2aab3b7b3b1b6b1ab1b5c26Aa","doi-asserted-by":"crossref","unstructured":"Eveno C, Haidara A, Ali I, Pimpie C, Mirshahi M, Pocard M. Experimental pharmacokinetics evaluation of chemotherapy delivery by PIPAC for colon cancer: first evidence for efficacy. Pleura Peritoneum 2017;2:103\u20139.30911638","DOI":"10.1515\/pp-2017-0015"},{"key":"2025120909273569346_j_pp-2019-0017_ref_027_w2aab3b7b3b1b6b1ab1b5c27Aa","doi-asserted-by":"crossref","unstructured":"Marple VA. History of impactors \u2013 The first 110\u2006years. Aerosol Sci Technol 2004;38:247\u201392.10.1080\/02786820490424347","DOI":"10.1080\/02786820490424347"},{"key":"2025120909273569346_j_pp-2019-0017_ref_028_w2aab3b7b3b1b6b1ab1b5c28Aa","unstructured":"Pabst UF, Bucur P, Demtr\u00f6der CR, H\u00f6lzen JP, Roger S, Tabchouri N et al. Gewebe und Blutkonzentration von Platin verabreicht mittels (e)PIPAC und L-HIPEC. 136. Kongress der Deutschan Gesellschaft f\u00fcr Chirurgie, M\u00fcnchen, 26\u201329 3 2019 (Abstract-ID:546)."},{"key":"2025120909273569346_j_pp-2019-0017_ref_029_w2aab3b7b3b1b6b1ab1b5c29Aa","doi-asserted-by":"crossref","unstructured":"Solass W, Struller F, Horvath P, K\u00f6nigsrainer A, Sipos B, Weinreich FJ. Morphology of the peritoneal cavity and pathophysiological consequences. Pleura Peritoneum 2016;1:193\u2013201.30911623","DOI":"10.1515\/pp-2016-0023"},{"key":"2025120909273569346_j_pp-2019-0017_ref_030_w2aab3b7b3b1b6b1ab1b5c30Aa","doi-asserted-by":"crossref","unstructured":"H\u00fcbner M. In search of evidence - PIPAC on the fast lane. Pleura Peritoneum 2018;3:20180119. DOI:10.1515\/pp-2018-0119.30911660","DOI":"10.1515\/pp-2018-0119"},{"key":"2025120909273569346_j_pp-2019-0017_ref_031_w2aab3b7b3b1b6b1ab1b5c31Aa","doi-asserted-by":"crossref","unstructured":"Minnaert AK, Dakwar GR, Benito JM, Garc\u00eda Fern\u00e1ndez JM, Ceelen W, De Smedt SC, et al. High-pressure nebulization as application route for the peritoneal administration of siRNA complexes. Macromol Biosci 2017;17:10.","DOI":"10.1002\/mabi.201700024"},{"key":"2025120909273569346_j_pp-2019-0017_ref_032_w2aab3b7b3b1b6b1ab1b5c32Aa","doi-asserted-by":"crossref","unstructured":"Solass W, Herbette A, Schwarz T, Hetzel A, Sun JS, Dutreix M, et al. Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum: proof of concept. Surg Endosc 2012;26:847\u201352.2204258510.1007\/s00464-011-1964-y","DOI":"10.1007\/s00464-011-1964-y"},{"key":"2025120909273569346_j_pp-2019-0017_ref_033_w2aab3b7b3b1b6b1ab1b5c33Aa","doi-asserted-by":"crossref","unstructured":"Mikolajczyk A, Khosrawipour V, Schubert J, Grzesiak J, Chaudhry H, Pigazzi A, et al. Effect of liposomal doxorubicin in pressurized intra-peritoneal aerosol chemotherapy (PIPAC). J Cancer 2018;9:4301\u20135.10.7150\/jca.2686030519333","DOI":"10.7150\/jca.26860"},{"key":"2025120909273569346_j_pp-2019-0017_ref_034_w2aab3b7b3b1b6b1ab1b5c34Aa","doi-asserted-by":"crossref","unstructured":"Schubert J, Khosrawipour V, Chaudhry H, Arafkas M, Knoefel WT, Pigazzi A, et al. Comparing the cytotoxicity of taurolidine, mitomycin C, and oxaliplatin on the proliferation of in vitro colon carcinoma cells following pressurized intra-peritoneal aerosol chemotherapy (PIPAC). World J Surg Oncol 2019;17:93.3115981910.1186\/s12957-019-1633-5","DOI":"10.1186\/s12957-019-1633-5"},{"key":"2025120909273569346_j_pp-2019-0017_ref_035_w2aab3b7b3b1b6b1ab1b5c35Aa","doi-asserted-by":"crossref","unstructured":"Mikolajczyk A, Khosrawipour V, Schubert J, Chaudhry H, Pigazzi A, Khosrawipour T. Particle stability during pressurized intra-peritoneal aerosol chemotherapy (PIPAC). Anticancer Res 2018;38:4645\u20139.10.21873\/anticanres.1276930061231","DOI":"10.21873\/anticanres.12769"},{"key":"2025120909273569346_j_pp-2019-0017_ref_036_w2aab3b7b3b1b6b1ab1b5c36Aa","doi-asserted-by":"crossref","unstructured":"Jung Do H, Son SY, Oo AM, Park YS, Shin DJ, Ahn SH, et al. Feasibility of hyperthermic pressurized intraperitoneal aerosol chemotherapy in a porcine model. Surg Endosc 2016;30:4258\u201364.10.1007\/s00464-015-4738-0","DOI":"10.1007\/s00464-015-4738-0"},{"key":"2025120909273569346_j_pp-2019-0017_ref_037_w2aab3b7b3b1b6b1ab1b5c37Aa","unstructured":"US FDA. Guidance for industry M3(R2) nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Available at: https:\/\/www.fda.gov\/media\/71542\/download. Accessed: 4 May 2019."},{"key":"2025120909273569346_j_pp-2019-0017_ref_038_w2aab3b7b3b1b6b1ab1b5c38Aa","doi-asserted-by":"crossref","unstructured":"Van de Sande L, Willaert W, Cosyns S, De Clercq K, Shariati M, Remaut K, et al. Establishment of a rat ovarian peritoneal metastasis model to study pressurized intraperitoneal aerosol chemotherapy (PIPAC). BMC Cancer 2019;19:424.10.1186\/s12885-019-5658-531064330","DOI":"10.1186\/s12885-019-5658-5"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/4\/3\/article-20190017.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0017\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0017\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:05:56Z","timestamp":1765278356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0017\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,15]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,10,11]]},"published-print":{"date-parts":[[2019,10,25]]}},"alternative-id":["10.1515\/pp-2019-0017"],"URL":"https:\/\/doi.org\/10.1515\/pp-2019-0017","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8,15]]},"article-number":"20190017"}}